PL373276A1 - Lek do stosowania przezskórnego do leczenia Zespołu Niespokojnych Nóg - Google Patents

Lek do stosowania przezskórnego do leczenia Zespołu Niespokojnych Nóg

Info

Publication number
PL373276A1
PL373276A1 PL03373276A PL37327603A PL373276A1 PL 373276 A1 PL373276 A1 PL 373276A1 PL 03373276 A PL03373276 A PL 03373276A PL 37327603 A PL37327603 A PL 37327603A PL 373276 A1 PL373276 A1 PL 373276A1
Authority
PL
Poland
Prior art keywords
sup
restless legs
legs syndrome
trans
administration form
Prior art date
Application number
PL03373276A
Other languages
English (en)
Other versions
PL218549B1 (pl
Inventor
Thomas Lauterbach
Erwin Schollmayer
Original Assignee
Schwarz Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29285132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL373276(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schwarz Pharma Ag filed Critical Schwarz Pharma Ag
Publication of PL373276A1 publication Critical patent/PL373276A1/pl
Publication of PL218549B1 publication Critical patent/PL218549B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Wynalazek dotyczy przezskórnej kompozycji farmaceutycznej zawierającej rotigotin, do skutecznego leczenia zespołu niespokojnych nóg (RLS), zwłaszcza w postaci przezskórnego układu leczniczego (TDS) na bazie akrylanu lub silikonu, mającego powierzchnię 2,5-20 cm<sup>2</sup> i zawierającego 1,125 do 9,0 mg/cm<sup>2</sup> rotigotinu jako aktywnego składnika przeciwko zespołowi niespokojnych nóg, który według skali oceny Międzynarodowej Grupy do Badania Zespołu Niespokojnych Nóg (IRLSSG), powoduje poprawę stanu pacjentów z zespołem niespokojnych nóg, w porównaniu z leczeniem 2 lub więcej jednostkami placebo, po podawaniu przez okres czasu co najmniej 8 dni.
PL373276A 2002-05-06 2003-05-05 Zastosowanie rotygotyny do wytwarzania leku do przezskórnego leczenia Zespołu Niespokojnych Nóg PL218549B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10220230A DE10220230A1 (de) 2002-05-06 2002-05-06 Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms

Publications (2)

Publication Number Publication Date
PL373276A1 true PL373276A1 (pl) 2005-08-22
PL218549B1 PL218549B1 (pl) 2014-12-31

Family

ID=29285132

Family Applications (1)

Application Number Title Priority Date Filing Date
PL373276A PL218549B1 (pl) 2002-05-06 2003-05-05 Zastosowanie rotygotyny do wytwarzania leku do przezskórnego leczenia Zespołu Niespokojnych Nóg

Country Status (23)

Country Link
EP (1) EP1501499B1 (pl)
JP (2) JP5253707B2 (pl)
KR (1) KR20040104697A (pl)
CN (1) CN100396281C (pl)
AT (1) ATE387912T1 (pl)
AU (1) AU2003233233B2 (pl)
BR (1) BR0309837A (pl)
CA (2) CA2483120C (pl)
CY (1) CY1107452T1 (pl)
DE (2) DE10220230A1 (pl)
DK (1) DK1501499T3 (pl)
ES (1) ES2301795T3 (pl)
IL (2) IL164861A0 (pl)
MX (1) MXPA04010687A (pl)
NO (1) NO333619B1 (pl)
NZ (1) NZ536533A (pl)
PL (1) PL218549B1 (pl)
PT (1) PT1501499E (pl)
RU (1) RU2301063C9 (pl)
SI (1) SI1501499T1 (pl)
UA (1) UA81625C2 (pl)
WO (1) WO2003092677A1 (pl)
ZA (1) ZA200408862B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
CN101460156B (zh) 2006-05-08 2011-06-08 帝国制药株式会社 抗痴呆药的经皮吸收制剂
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
PL2215072T3 (pl) 2007-11-28 2015-12-31 Ucb Pharma Gmbh Polimorficzna postać rotygotyny
JP5537412B2 (ja) 2008-02-27 2014-07-02 久光製薬株式会社 貼付製剤
ES2661767T3 (es) 2008-02-27 2018-04-03 Hisamitsu Pharmaceutical Co., Inc. Parche adhesivo para la piel y producto envasado
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
WO2011076879A1 (en) * 2009-12-22 2011-06-30 Ucb Pharma Gmbh Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
EP2531486B1 (en) 2010-02-05 2017-06-21 UCB Biopharma SPRL Novel process for the preparation of nitrogen substituted aminotetralins derivatives
CA2798815C (en) 2010-06-25 2017-01-03 Ucb Pharma Gmbh Novel process for the preparation of nitrogen substituted aminotetralins derivatives
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
DE102012013439A1 (de) 2012-07-03 2014-01-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
WO2013075822A1 (en) 2011-11-22 2013-05-30 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermal therapeutic system (tts) with rotigotine
DE102012013421A1 (de) 2012-07-03 2014-01-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TTS) mit Rotigotin
KR101558042B1 (ko) * 2012-07-05 2015-10-07 에스케이케미칼주식회사 로티고틴을 함유한 경피흡수제제
JP2015522013A (ja) * 2012-07-06 2015-08-03 エスケー ケミカルス カンパニー リミテッド ロチゴチン含有経皮吸収製剤
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
CN105358139B (zh) 2013-07-03 2020-10-16 Lts罗曼治疗方法有限公司 具有电子元件的经皮治疗系统
US10045948B2 (en) 2014-02-27 2018-08-14 Medrx Co., Ltd. Pramipexole-containing transdermal patch for treatment of neurodegenerative disease
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
ES2954087T3 (es) 2014-05-20 2023-11-20 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que incluye un mediador de interfase
JP6573913B2 (ja) 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
ES2962896T3 (es) 2019-06-14 2024-03-21 Hisamitsu Pharmaceutical Co Parche que contiene rotigotina
DK3854388T3 (da) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermalt terapeutisk system omfattende rotigotin og mindst et ikke-aminresistent silikoneklæbestof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5232702A (en) * 1991-07-22 1993-08-03 Dow Corning Corporation Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices
DE4238223C1 (de) * 1992-11-12 1994-05-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von Physostigmin an die Haut und Verfahren zu dessen Herstellung
US5482988A (en) * 1994-01-14 1996-01-09 Dow Corning Corporation Hot-melt silicone pressure sensitive adhesive with siloxylated polyether waxes as additives
IL116539A (en) * 1995-01-06 2002-02-10 Noven Pharma Preparations given through the skin of unstable anti-acid drugs
FR2749514B1 (fr) * 1996-06-11 1998-08-07 Hoechst Marion Roussel Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19938825A1 (de) * 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
ES2204780T3 (es) * 2001-05-08 2004-05-01 Schwarz Pharma Ag Sistema terapeutico transdermico para la enfermedad de parkinson que induce altos niveles de rotigotina en plasma.
PT1256340E (pt) * 2001-05-08 2003-12-31 Sanol Arznei Schwarz Gmbh Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson

Also Published As

Publication number Publication date
AU2003233233B2 (en) 2008-03-06
EP1501499A1 (de) 2005-02-02
ZA200408862B (en) 2005-09-28
NZ536533A (en) 2010-02-26
PT1501499E (pt) 2008-05-20
CA2483120A1 (en) 2003-11-13
HK1072541A1 (zh) 2005-09-02
IL164861A0 (en) 2005-12-18
ATE387912T1 (de) 2008-03-15
JP5253707B2 (ja) 2013-07-31
IL164861A (en) 2011-06-30
JP2010159302A (ja) 2010-07-22
EP1501499B1 (de) 2008-03-05
DE50309318D1 (de) 2008-04-17
RU2004131866A (ru) 2005-06-10
AU2003233233A1 (en) 2003-11-17
CY1107452T1 (el) 2012-12-19
KR20040104697A (ko) 2004-12-10
JP2005528413A (ja) 2005-09-22
CN100396281C (zh) 2008-06-25
DK1501499T3 (da) 2008-06-23
CA2787384A1 (en) 2003-11-13
RU2301063C9 (ru) 2007-11-27
MXPA04010687A (es) 2005-06-08
SI1501499T1 (sl) 2008-06-30
CN1665497A (zh) 2005-09-07
ES2301795T3 (es) 2008-07-01
PL218549B1 (pl) 2014-12-31
NO20045240L (no) 2004-11-30
UA81625C2 (ru) 2008-01-25
RU2301063C2 (ru) 2007-06-20
DE10220230A1 (de) 2003-11-27
CA2483120C (en) 2013-07-16
NO333619B1 (no) 2013-07-22
BR0309837A (pt) 2005-03-01
WO2003092677A1 (de) 2003-11-13

Similar Documents

Publication Publication Date Title
CY1107452T1 (el) Διαδερμικη μορφη χορηγησης για τη θεραπεια του συνδρομου ανησυχων ποδιων
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
IL186655A0 (en) Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations
BRPI0414481A (pt) métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica
PT1256340E (pt) Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
RU2003133217A (ru) Чрескожная терапевтическая система для лечения болезни паркинсона, индуцирующая высокие уровни ротиготина в плазме
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
PL402550A1 (pl) Dopochwowe kompozycje farmaceutyczne oraz zastosowanie zródla nadtlenku i bioadhezyjnego nosnika
BRPI0407178A (pt) Composição farmacêutica osteogênica
MXPA03010679A (es) Una composicion para acelerar la cicatrizacion de fractura osea.
ATE350032T1 (de) Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen
UY26595A1 (es) Formulaciones de entecavir de dosis bajas y uso
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
SE0102887D0 (sv) New formulation
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
TW200618807A (en) Prevention and therapeutical agent for hepatitis C virus infection
SE0002354D0 (sv) New formulation
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica
HRP20070441T3 (hr) Farmaceutska kombinacija za liječenje grčeva i/ili boli
BR0215352A (pt) Composição farmacêutica que compreende um inibidor de alfa-glicosidase e um ácido 4-oxobutanóico, e seu uso para tratar diabetes